Moleculin Biotech Inc., a late-stage pharmaceutical company, has reported its financial results for the first quarter of 2025, which ended on March 31. The company revealed that its research and development (R&D) expenses decreased to $3.4 million from $4.3 million in the same period of 2024, primarily due to variations in clinical trial activity levels. General and administrative expenses slightly increased to $2.5 million from $2.4 million in the previous year, attributed to a rise in regulatory and legal fees. As of March 31, 2025, Moleculin held cash and cash equivalents totaling $7.7 million, which the company believes is sufficient to fund its planned operations into the third quarter of 2025. The company is actively progressing with its pivotal Phase 3 MIRACLE trial for Annamycin, targeting relapsed or refractory acute myeloid leukemia (R/R AML), with European Medicines Agency (EMA) approval extending the trial to nine additional countries. Enrollment and dosing are currently underway, with interim data expected in the second half of 2025. Additionally, Moleculin has initiated a collaboration with Emory University to study WP1066 IV formulations in preclinical settings, with results anticipated in the latter half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.